<DOC>
	<DOC>NCT00725582</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a screening period and a treatment period which includes doses on day 1 and day 8.</brief_summary>
	<brief_title>Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1. Healthy men and women 18 to 60 yrs with mild allergic asthma 2. only asthma med is shortacting bronchodilator used not more than twice weekly 3. FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction 1. Upper respiratory infection or asthma exacerbation with 4 weeks of screening 2. Serious infection requiring parenteral antibiotics or hospitalization with 4 weeks of test article administration 3. Positive radiographic findings indicative of respiratory disease other than asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>